Trusted Resources: Education
Scientific literature and patient education texts
Mucopolysaccharidosis II (MPS II) in a Free-Living Kaka (Nestor Meridionalis) in New Zealand
source: Journal of wildlife diseases
year: 2021
authors: Jolly RD,Hunter SA,Alley MR,King BM,Lau AA,Trim PJ,Snel MF,Hemsley KM
summary/abstract:A lysosomal storage disease, identified as a mucopolysaccharidosis (MPS), was diagnosed in a free-living Kaka (Nestor meridionalis), an endemic New Zealand parrot, which exhibited weakness, incoordination, and seizures. Histopathology showed typical colloid-like cytoplasmic inclusions in Purkinje cells and many other neurons throughout the brain. Electron microscopy revealed that storage bodies contained a variety of linear, curved, or circular membranous profiles and electron-dense bodies. Because the bird came from a small isolated population of Kaka in the northern South Island, a genetic cause was deemed likely. Tandem mass spectrometry revealed increased levels of heparan sulfate-derived disaccharides in the brain and liver compared with tissues from controls. Enzymatic assays documented low levels of iduronate-2-sulfatase activity, which causes a lysosomal storage disorder called MPS type II or Hunter syndrome. A captive breeding program is currently in progress, and the possibility of detecting carriers of this disorder warrants further investigation.
organization: School of Veterinary Science, Massey University, New ZealandDOI: 10.7589/JWD-D-20-00173
read more
Related Content
-
Functioning Profiles of Individuals With Mucopolysaccharidosis According to the International Classification of Func...The classification of health problems of...
-
Features and Behavior of Valvular Abnormalities in Adolescent and Adult Patients in Mucopolysaccharidosis: An Echoca...Mucopolysaccharidoses, a rare inherited ...
-
Facial and Cephalometric Features of Individuals With Mucopolysaccharidosis: A Cross-Sectional StudyThe aim was to assess craniofacial featu...
-
Mucopolysaccharidosis Type 1 (MPS 1)What is Mucopolysaccharidosis Type 1?Muc...
-
Real-World Data Assessment of Safety of Home-Based and Hospital/Outpatient-Based laronidase Enzyme Replacement Thera...Enzyme replacement therapy (ERT) is avai...
-
A Rare Specialism: A Look at the Last Ten Years in MPS Management, Presented by Dr Christina Lampehttps://www.youtube.com/watch?v=EjNEVoWT...
-
International MPS NetworkCreated in April 1992 by Christine Laver...